nach oben

Current Urology Reports

Erschienen in:

01.02.2013 | Kidney Diseases (G Ciancio, Section Editor)

Small Renal Mass: To Treat or Not To Treat

verfasst von: Ahmed Alasker, Steve K. Williams, Reza Ghavamian

Erschienen in: Current Urology Reports | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

An increasing number of small renal masses (SRMs) are being detected with modern cross-sectional imaging. The natural history of SRMs is mostly unknown. Initial active surveillance (AS) is a reasonable treatment option for small renal masses (SRMs) < 4 cm in the infirm patient with major comorbidities. Partial nephrectomy (PN) is the established treatment for T1a tumors, provided that the operation is technically feasible and the tumor can be completely removed. Laparoscopic and, most recently, robotic PN have functional and oncologic outcomes comparable to open PN, but are technically demanding procedures. Radical nephrectomy (RN) should be limited to those cases where the tumor is not amenable to PN. Percutaneous needle biopsy of SRMs can be safely performed and has the potential to characterize SRMs histologically. It is best utilized in conjunction with ablative technologies. However, ablative therapies should be reserved for carefully selected patients who are poor surgical candidates.

• Cancer Facts & Figures, 2012. American Cancer Society. Available at http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed September 2012. A recent overview of cancer statistics in the United States.

Chow W, Devesa SS, Warren JL, Fraumeni JJF. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281(17):1628–31. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-17-joc81613.PubMedCrossRef

Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Canc Inst. 2006;98(18):1331–4. doi:10.1093/jnci/djj362.CrossRef

Chow W-H, Gridley G, Fraumeni JF, Järvholm B. Obesity, hypertension, and the risk of kidney cancer in men. New Engl J Med. 2000;343(18):1305–11. doi:10.1056/NEJM200011023431804.PubMedCrossRef

Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78. doi:10.1016/s0140-6736(08)60269-x.PubMedCrossRef

Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Canc. 2005;114(1):101–8. doi:10.1002/ijc.20618.CrossRef

Muscat JE, Hoffmann D, Wynder EL. The epidemiology of renal cell carcinoma. A second look. Cancer. 1995;75(10):2552–7. doi:10.1002/1097-0142(19950515)75:10<2552::aid-cncr2820751023>3.0.co;2-1.PubMedCrossRef

Ghavamian R. Management of the small renal mass: what is the most reasonable option? Expet Rev Anticancer Ther. 2011;11(7):979–82. doi:10.1586/era.11.87.CrossRef

Remzi M, Özsoy M, Klingler HC, Susani M, Waldert M, Seitz C, et al. Are small renal tumors harmless? analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol. 2006;176(3):896–9. doi:10.1016/j.juro.2006.04.047.PubMedCrossRef

10.

Klatte T, Patard J-J, de Martino M, Bensalah K, Verhoest G, de la Taille A, et al. Tumor size does Not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol. 2008;179(5):1719–26. doi:10.1016/j.juro.2008.01.018.PubMedCrossRef

11.

Kume H, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, et al. Distant metastasis of renal cell carcinoma with a diameter of 3 cm or less—which is aggressive cancer? J Urol. 2010;184(1):64–8.PubMedCrossRef

12.

• Mason RJ, Abdolell M, Trottier G, Pringle C, Lawen JG, Bell DG, et al. Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol. 2011;59(5):863–7. doi:10.1016/j.eururo.2011.02.023. An elegant prospective study showing a cut of < 2.45 cm is associated with slower growth rate.PubMedCrossRef

13.

Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DYT, Uzzo RG. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer. 2009;115(13):2844–52. doi:10.1002/cncr.24338.PubMedCrossRef

14.

Kato M, Suzuki T, Suzuki Y, Terasawa Y, Sasano H, Arai Y. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J Urol. 2004;172(3):863–6. doi:10.1097/01.ju.0000136315.80057.99.PubMedCrossRef

15.

Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DYT, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175(2):425–31. doi:10.1016/s0022-5347(05)00148-5.PubMedCrossRef

16.

•• Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DYT, et al. Small renal masses progressing to metastases under active surveillance. Cancer. 2012;118(4):997–1006. doi:10.1002/cncr.26369. A recent meta-analysis of SRMs under active surveillance with highlight of their risk of metastasis.PubMedCrossRef

17.

Beisland C, Hjelle KM, Reisæter LAR, Bostad L. Observation should be considered as an alternative in management of renal masses in older and comorbid patients. Eur Urol. 2009;55(6):1419–29. doi:10.1016/j.eururo.2008.12.031.PubMedCrossRef

18.

Lebret T, Poulain JE, Molinie V, Herve JM, Denoux Y, Guth A, et al. Percutaneous core biopsy for renal masses: indications, accuracy and results. J Urol. 2007;178(4):1184–8. doi:10.1016/j.juro.2007.05.155.PubMedCrossRef

19.

Volpe A, Kachura JR, Geddie WR, Evans AJ, Gharajeh A, Saravanan A, et al. Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol. 2007;178(2):379–86. doi:10.1016/j.juro.2007.03.131.PubMedCrossRef

20.

Volpe A, Mattar K, Finelli A, Kachura JR, Evans AJ, Geddie WR, et al. Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J Urol. 2008;180(6):2333–7. doi:10.1016/j.juro.2008.08.014.PubMedCrossRef

21.

Leveridge MJ, Finelli A, Kachura JR, Evans A, Chung H, Shiff DA, et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol. 2011;60(3):578–84. doi:10.1016/j.eururo.2011.06.021.PubMedCrossRef

22.

Shannon BA, Cohen RJ, de Bruto H, Davies RJ. The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses. J Urol. 2008;180(4):1257–61. doi:10.1016/j.juro.2008.06.030.PubMedCrossRef

23.

Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006;7(9):735–40. doi:10.1016/s1470-2045(06)70803-8.PubMedCrossRef

24.

• Tan H, Norton EC, Ye Z, Hafez KS, Gore JL, Miller DC. Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA. 2012;307(15):1629–35. doi:10.1001/jama.2012.475. A large population study showing a survival advantage of PN over RN.PubMedCrossRef

25.

Zini L, Perrotte P, Capitanio U, Jeldres C, Shariat SF, Antebi E, et al. Radical versus partial nephrectomy. Cancer. 2009;115(7):1465–71. doi:10.1002/cncr.24035.PubMedCrossRef

26.

•• Sun M, Trinh Q-D, Bianchi M, Hansen J, Hanna N, Abdollah F, et al. A Non–cancer-related survival benefit is associated with partial nephrectomy. Eur Urol. 2012;61(4):725–31. doi:10.1016/j.eururo.2011.11.047. A matched analysis of patients with SRMs in a large population study confirming the superiority of PN over RN.PubMedCrossRef

27.

Lane BR, Gill IS. 7-Year oncological outcomes after laparoscopic and open partial nephrectomy. J Urol. 2010;183(2):473–9. doi:10.1016/j.juro.2009.10.023.PubMedCrossRef

28.

Gill IS, Kavoussi LR, Lane BR, Blute ML, Babineau D, Colombo Jr JR, et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol. 2007;178(1):41–6. doi:10.1016/j.juro.2007.03.038.PubMedCrossRef

29.

Abouassaly R, Alibhai SMH, Tomlinson G, Timilshina N, Finelli A. Unintended consequences of laparoscopic surgery on partial nephrectomy for kidney cancer. J Urol. 2010;183(2):467–72. doi:10.1016/j.juro.2009.10.002.PubMedCrossRef

30.

Benway BM, Bhayani SB, Rogers CG, Dulabon LM, Patel MN, Lipkin M, et al. Robot assisted partial nephrectomy versus laparoscopic partial nephrectomy for renal tumors: a multi-institutional analysis of perioperative outcomes. J Urol. 2009;182(3):866–73. doi:10.1016/j.juro.2009.05.037.PubMedCrossRef

31.

•• Aboumarzouk OM, Stein RJ, Eyraud R, Haber G-P, Chlosta PL, Somani BK, et al. Robotic versus laparoscopic partial nephrectomy: a systematic review and meta-analysis. Eur Urol. 2012. doi:10.1016/j.eururo.2012.06.038. A recent meta-analysis comparing RALPN vs. LPN.

32.

Long J-A, Yakoubi R, Lee B, Guillotreau J, Autorino R, Laydner H, et al. Robotic versus laparoscopic partial nephrectomy for complex tumors: comparison of perioperative outcomes. Eur Urol. 2012;61(6):1257–62. doi:10.1016/j.eururo.2012.03.012.PubMedCrossRef

33.

Simhan J, Smaldone MC, Tsai KJ, Li T, Reyes JM, Canter D, et al. Perioperative outcomes of robotic and open partial nephrectomy for moderately and highly complex renal lesions. J Urol. 2012;187(6):2000–4. doi:10.1016/j.juro.2012.01.064.PubMedCrossRef

34.

Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma—a meta-analysis and review. J Urol. 2008;179(4):1227–34. doi:10.1016/j.juro.2007.11.047.PubMedCrossRef

35.

Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass. Cancer. 2008;113(10):2671–80. doi:10.1002/cncr.23896.PubMedCrossRef

36.

Tracy CR, Raman JD, Donnally C, Trimmer CK, Cadeddu JA. Durable oncologic outcomes after radiofrequency ablation. Cancer. 2010;116(13):3135–42. doi:10.1002/cncr.25002.PubMedCrossRef

37.

Weight CJ, Kaouk JH, Hegarty NJ, Remer EM, O’Malley CM, Lane BR, et al. Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. J Urol. 2008;179(4):1277–83. doi:10.1016/j.juro.2007.11.075.PubMedCrossRef

38.

•• Guideline for Management of the Clinical Stage 1 Renal Mass. American Urological Association 2009. Available at http://www.auanet.org/content/clinical-practice-guidelines/clinical-guidelines.cfm. Accessed September 2012. The latest version of AUA guidelines which offers a nice overview for SRMs management.

39.

Nguyen CT, Lane BR, Kaouk JH, Hegarty N, Gill IS, Novick AC, et al. Surgical salvage of renal cell carcinoma recurrence after thermal ablative therapy. J Urol. 2008;180(1):104–9. doi:10.1016/j.juro.2008.03.046.PubMedCrossRef

Titel: Small Renal Mass: To Treat or Not To Treat
verfasst von: Ahmed Alasker
Steve K. Williams
Reza Ghavamian
Publikationsdatum: 01.02.2013
Verlag: Current Science Inc.
Erschienen in: Current Urology Reports / Ausgabe 1/2013
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-012-0296-3

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Lymphadenectomy with Robotic Cystectomy

Robot-Assisted Laparoscopic Bladder Diverticulectomy

Robotic Assisted Laparoscopic Mitrofanoff Appendicovesicostomy (RALMA)

Partial Nephrectomy: Is There Still a Need for Open Surgery?

Robotic Assisted Ureteral Reimplantation: Current Status